Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

EZETIMIBE

All products: Limited Use (codes 380, 381)

Other products in the same Health Canada class (C10A, C10AX) — coverage varies; not interchangeable

  • Alirocumab (Praluent): limited Use 555
  • Evolocumab (Repatha): limited Use 527, 737
  • Inclisiran (Leqvio): limited Use 732
  • Atorvastatin (Lipitor): general benefit
  • Bezafibrate (Bezalip): general benefit
  • Cholestyramine resin (Questran Light 4g Pk): general benefit, Not a benefit

9 more in the class list below

Ezetrol · DIN 02247521 · 10mg · tablet

Limited Use — Reason for Use code 380, 381 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 380, 381 required
Write on scriptLU code 380, 381 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 380, 381
Reason for Use code 380 For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 381 For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated. Coverage limit: LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Ezetrol (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Ezetrol · DIN 02247521 Manufacturer: Organon Canada Inc.; listing date 2004-04-06 Health Canada: Marketed since 2022-04-22 · brand EZETROL · ATC C10AX09 EZETIMIBE · form Tablet · route Oral · ingredients EZETIMIBE 10 MG · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1811 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71771 · Verify on the e-Formulary ↗ (DIN 02247521)

Source record
DIN 02247521: Ezetrol Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 240600049; group id 302; item number 0656; lccId 00150; manufacturer id OCI Source form: Tab; strength: 10mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $2.2508; ministry $0.1811 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247521 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71771
Interchangeable products
AG-Ezetimibe · DIN 02475898 · $0.1811 Ach-Ezetimibe · DIN 02425610 · $0.1811 Act Ezetimibe · DIN 02414716 · $0.1811 Apo-Ezetimibe · DIN 02427826 · $0.1811 Auro-Ezetimibe · DIN 02469286 · $0.1811 Bio-Ezetimibe · DIN 02425211 · $0.1811 Ezetimibe · DIN 02429659 · $0.1811 Ezetimibe · DIN 02431300 · $0.1811 GLN-Ezetimibe · DIN 02460750 · $0.1811 Jamp-Ezetimibe · DIN 02423235 · $0.1811 M-Ezetimibe · DIN 02467437 · $0.1811 Mar-Ezetimibe · DIN 02422662 · $0.1811 Mint-Ezetimibe · DIN 02423243 · $0.1811 NRA-Ezetimibe · DIN 02481669 · $0.1811 NRA-Ezetimibe Tablets · DIN 02536420 · $0.1811 PMS-Ezetimibe · DIN 02416409 · $0.1811 Ran-Ezetimibe · DIN 02419548 · $0.1811 Sandoz Ezetimibe · DIN 02416778 · $0.1811 Teva-Ezetimibe · DIN 02354101 · $0.1811
Shortage status: resolved shortage (ended 2024-11-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02247521
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:06 Antilipemic Drugs) and how they are covered

Matched class: 24:06 Antilipemic Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, BEZAFIBRATE, ROSUVASTATIN CALCIUM Some products covered without a code (check the product listing): CHOLESTYRAMINE RESIN, COLESEVELAM HYDROCHLORIDE, FENOFIBRATE, FLUVASTATIN SODIUM, GEMFIBROZIL, LOVASTATIN, PRAVASTATIN SODIUM, SIMVASTATIN 24:00 CARDIOVASCULAR DRUGS

INCLISIRAN

· 1 products · Limited Use, codes 732 · strengths: 284mg/1.5mL · Inj Sol-1.5mL Pref Syr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:06 Antilipemic Drugs

EVOLOCUMAB

· 1 products · Limited Use, codes 527, 737 · strengths: 140mg/mL · Inj Sol-Pref Syr Autoinj

ATORVASTATIN CALCIUM

· 99 products · General benefit · strengths: 10mg, 20mg, 40mg, 80mg · Tab

BEZAFIBRATE

· 2 products · General benefit · strengths: 400mg · SR Tab

CHOLESTYRAMINE RESIN

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: · Oral Pd-Pouch Pk

COLESEVELAM HYDROCHLORIDE

· 3 products · General benefit (2), Temporary benefit (1) · strengths: 625mg · Tab

FENOFIBRATE

· 16 products · Listed, not a benefit (2), General benefit (9), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 100mg, 67mg, 200mg, 160mg, 48mg, 145mg · Cap, Tab

FLUVASTATIN SODIUM

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 20mg, 40mg, 80mg · Cap, ER Tab

GEMFIBROZIL

· 6 products · Listed, not a benefit (1), General benefit (2), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 300mg, 600mg · Cap, Tab

LOVASTATIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 20mg, 40mg · Tab

PRAVASTATIN SODIUM

· 57 products · Listed, not a benefit (3), General benefit (54) · strengths: 10mg, 20mg, 40mg · Tab

ROSUVASTATIN CALCIUM

· 80 products · General benefit · strengths: 5mg, 10mg, 20mg, 40mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:06 and 4 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication:
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. AMBRISENTAN · Off-Formulary Interchangeable, not an ODB benefit Indications VOLIBRIS (ambrisentan tablets) is indicated for: • The treatment of idiopathic (‘primary’) pulmonary arterial hypertension (IPAH) and pulmonary arterial hypertension (PAH) associated with connective tissue disease in adult patients with WHO functional class II or III symptoms. PM: https://pdf.hres.ca/dpd_pm/00082650.PDF; date 2025-12-02; DIN 02307065; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS EZETROL® (ezetimibe) is indicated as an adjunct to lifestyle changes, including diet, when the response to diet and other non-pharmacological measures alone has been inadequate. Primary Hypercholesterolemia EZETROL, administered alone or with an HMG-CoA reductase inhibitor (statin), is indicated for: • the reduction of elevated total cholesterol (total-C), low density lipoprotein cholesterol (LDL C), apolipoprotein B (Apo B), and triglycerides (TG) and • to increase high density lipoprotein cholesterol (HDL-C) in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. EZETROL, administered in combination with fenofibrate, is indicated for: • the reduction of elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia. Homozygous Familial Hypercholesterolemia (HoFH) EZETROL, administered with a statin, is indicated for: • the reduction of elevated total-C and LDL-C levels in patients with HoFH as an adjunct to treatments such as LDL apheresis or if such treatments are not possible. Homozygous Sitosterolemia (Phytosterolemia) EZETROL is indicated for: • the reduction of… https://pdf.hres.ca/dpd_pm/00074278.PDF PM date: JUN 15, 2003 Source product: EZETROL; DIN 02247521; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.